Clinical Trial Update: Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial updates the use of a combination of amrubicin and irinotecan for patients with recurrent or relapsed extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Amrubicin (amrubicin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Japan Multinational Trial Organization | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED